Blue Sky Stock Volatility Report

Notable Movers & Volatility

MRNA dominated the tape, running +235.47% from $52.66 to $176.66 and posting a 376.49% realized volatility against 136.06% implied — an 8.02x vol surprise, the largest in the report. It closed at $142.64, 72.56% of its range, giving back some of the extreme. STIM (+90.58%) and TEM (+65.59%) followed, with TEM closing nearest its high at 98.78% and HIMS (+36.80%) at 90.02%.

The downside was equally violent: KPTI fell -75.97% with 416.85% realized vol and closed at just 1.76% of its range; EBS (-43.38%, 4.85x realized/implied) closed at 7.93%. CVS (-15.45%, 4.30%) and UNH (-10.52%, 2.18%) also finished on their lows.

Options were mispriced in both directions. Realized exceeded implied for most names — SYK (3.77x), BNTX (3.31x), TEM (3.19x), MRK (3.17x) — while premium was overpriced in CDXS (0.50x, 216.41% IV), DBVT (0.41x) and MGNX (0.97x), where triple-digit implieds far outran actual movement. Large caps (ABT, JNJ, XLV) moved modestly but still ran ~2x implied.

Broader Market Context

Dispersion within the sector was extreme. The gap between MRNA's +235.47% and KPTI's -75.97% spans over 300 percentage points inside a single sector, which is far wider than typical index-level dispersion and argues that this was not one macro shock hitting all health names equally. The sub-groups pulled apart cleanly:

• Biotech/clinical-stage names (MRNA, BNTX, QURE, ANAB, MGNX, KPTI, EBS) posted the widest tails in both directions, with realized vols from 43% to 417%.
• Large-cap pharma (MRK +21.61%, AMGN +17.88%, LLY +16.54%, GILD +16.13%, ABT, JNJ, BMY) advanced in a tight, orderly 10–22% band with realized vols mostly in the 20s–40s.
• Managed care/payors (UNH, HUM, CI, CVS, CNC, ELV) were the clear laggards — four of the six negative and CVS, UNH and CI all closing near range lows.
• Providers and services (THC +13.63%, ADUS +14.50%) tracked closer to the pharma cohort than the payors.

Rotation vs. idiosyncratic. The broad-based advance in mega-cap pharma plus XLV (+9.87%, closing at 87.08% of range) is consistent with money rotating *into* defensive health exposure, the kind of move often seen when investors trim cyclical or high-beta risk. But the payor weakness cuts against a clean defensive bid — that divergence looks more like a business-line-specific repricing than a sector-wide flow. And the biotech tails are almost certainly idiosyncratic: single-name moves of that magnitude, with realized vol running 3–8x implied, are far more typical of binary catalysts (trial readouts, regulatory decisions, partnership or acquisition speculation) than of macro rotation.

Plausible current-events backdrop. Several themes could reasonably relate to this pattern, though none is confirmed by the data:

• Ongoing drug-pricing and reimbursement policy uncertainty, which historically weighs on payors and PBM-linked names more than on innovators.
• A heavy summer catalyst calendar for clinical-stage biotech, consistent with the very high implieds in CDXS (216%), KPTI (204%) and DBVT (168%) — where options markets were clearly pricing binary risk, correctly in KPTI's case and expensively in CDXS's.
• Rate expectations and risk appetite, which tend to amplify long-duration biotech moves relative to cash-generative large caps.

Positioning takeaway: implied vol underpriced realized in roughly two-thirds of these names, so premium-selling in health during this window was broadly unrewarded outside a handful of overpriced micro-caps.